Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

91 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Neutrophil-to-lymphocyte ratio and all-cause mortality with and without myeloproliferative neoplasms-a Danish longitudinal study.
Larsen MK, Skov V, Kjær L, Eickhardt-Dalbøge CS, Knudsen TA, Kristiansen MH, Sørensen AL, Wienecke T, Andersen M, Ottesen JT, Gudmand-Høyer J, Snyder JA, Andersen MP, Torp-Pedersen C, Poulsen HE, Stiehl T, Hasselbalch HC, Ellervik C. Larsen MK, et al. Among authors: skov v. Blood Cancer J. 2024 Feb 9;14(1):28. doi: 10.1038/s41408-024-00994-z. Blood Cancer J. 2024. PMID: 38331919 Free PMC article.
Safety and efficacy of combination therapy of interferon-α2 and ruxolitinib in polycythemia vera and myelofibrosis.
Mikkelsen SU, Kjaer L, Bjørn ME, Knudsen TA, Sørensen AL, Andersen CBL, Bjerrum OW, Brochmann N, Fassi DE, Kruse TA, Larsen TS, Mourits-Andersen HT, Nielsen CH, Pallisgaard N, Thomassen M, Skov V, Hasselbalch HC. Mikkelsen SU, et al. Among authors: skov v. Cancer Med. 2018 Aug;7(8):3571-3581. doi: 10.1002/cam4.1619. Epub 2018 Jun 22. Cancer Med. 2018. PMID: 29932310 Free PMC article. Clinical Trial.
B-cell frequencies and immunoregulatory phenotypes in myeloproliferative neoplasms: Influence of ruxolitinib, interferon-α2, or combination treatment.
Sørensen AL, Bjørn ME, Riley CH, Holmstrøm M, Andersen MH, Svane IM, Mikkelsen SU, Skov V, Kjaer L, Hasselbalch HC, Nielsen CH. Sørensen AL, et al. Among authors: skov v. Eur J Haematol. 2019 Oct;103(4):351-361. doi: 10.1111/ejh.13292. Epub 2019 Aug 18. Eur J Haematol. 2019. PMID: 31297883 Clinical Trial.
Smoking, blood cells and myeloproliferative neoplasms: meta-analysis and Mendelian randomization of 2·3 million people.
Jayasuriya NA, Kjaergaard AD, Pedersen KM, Sørensen AL, Bak M, Larsen MK, Nordestgaard BG, Bojesen SE, Çolak Y, Skov V, Kjaer L, Tolstrup JS, Hasselbalch HC, Ellervik C. Jayasuriya NA, et al. Among authors: skov v. Br J Haematol. 2020 Apr;189(2):323-334. doi: 10.1111/bjh.16321. Epub 2019 Dec 25. Br J Haematol. 2020. PMID: 31875952 Free article.
Data-driven analysis of JAK2V617F kinetics during interferon-alpha2 treatment of patients with polycythemia vera and related neoplasms.
Pedersen RK, Andersen M, Knudsen TA, Sajid Z, Gudmand-Hoeyer J, Dam MJB, Skov V, Kjaer L, Ellervik C, Larsen TS, Hansen D, Pallisgaard N, Hasselbalch HC, Ottesen JT. Pedersen RK, et al. Among authors: skov v. Cancer Med. 2020 Mar;9(6):2039-2051. doi: 10.1002/cam4.2741. Epub 2020 Jan 28. Cancer Med. 2020. PMID: 31991066 Free PMC article.
91 results